Carolyn Vachani, RN, MSN, AOCN
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 25 de octubre del 2005
This presentation reviewed a recent study involving postmenopausal women with early stage, hormone receptor positive breast cancer (ER+ or PR+). Some have wondered if treating these patients with lumpectomy, radiation and tamoxifen was "over treating". Would these women do just as well without the radiation, saving 6 weeks of daily trips to the radiation center and the associated side effects? One recent study (CALGB 9343) showed better disease-free survival (99% vs. 94.4%) when these women received radiation. The current study assigned women with early breast cancer from 1/96 through 6/04 to receive either lumpectomy, radiation, and tamoxifen or Arimidex (LR), or lumpectomy and tamoxifen or Arimidex (LH). Thus far, there have been a significantly higher number of recurrences at the original site of the cancer in the group that did not get radiation (13 patients vs. 1 patient in the LR group). Despite this finding, metastasis to other areas of the body and overall patient survival are equal in the two groups. This study stopped accruing patients in June 2004, so it is relatively early in the data collection. Further follow-up will help better clarify this question but, for now, radiation remains a part of the standard of care.English
Oct 23, 2014 - A three week course of radiation treatment may be as effective as six weeks or more in patients with early-stage breast cancer, according to research presented at the 51st Annual Meeting of the American Society for Radiation Oncology, held from Nov. 1 to 5 in Chicago. In a related study presented at the meeting, adding radiation to the internal mammary lymph nodes does not improve survival in patients with early-stage breast cancer.